Clonoseq Login

clonoSEQ Process | Ordering – Adaptive Biotechnologies  

https://www.adaptivebiotech.com/clonoseq/ordering

Order clonoSEQ through Adaptive’s CLIA-certified and CAP-accredited lab. Contact Adaptive to learn more about ordering clonoSEQ testing services for your patients. … The clonoSEQ Assay is currently availabl…

Login – Adaptive Biotechnologies  

https://clients.adaptivebiotech.com/login

Expedite and streamline the peer-review process by sharing your data in an interactive format with reviewers, enabling them to explore your data directly within …

clonoSEQ Report | Adaptive Biotechnologies  

https://www.adaptivebiotech.com/clonoseq/clonoseq-report

Clinicians receive clonoSEQ test results via an informative clinical report. These visually … when needed. Log in to access your patients’ clonoSEQ test results.

FDA-Cleared | clonoSEQ  

https://www.clonoseq.com/now-fda-cleared

clonoSEQ is FDA cleared for the detection and monitoring of measurable residual disease (MRD) in bone marrow samples from myeloma and B-ALL patients.

clonoSEQ  

Home HCP

Log In · Request Account. EXPANDED COVERAGE. Positive payer coverage decisions expand clonoSEQ access to over 140 million people. Read full story >.

clonoSEQ Assay Authorized for Detection of MRD in Patients With MM …  

https://www.clinicaloncology.com/FDA-Watch/Article/10-18/clonoSEQ-Assay-Authorized-for-Detection-of-MRD-in-Patients-With-MM-and-B-Cell-ALL/53115

Oct 22, 2018 – The FDA has authorized use of the clonoSEQ Assay (Adaptive Biotechnologies) to monitor and detect minimal residual disease in patients with …

Adaptive Biotechnologies Announces Medicare Coverage of the …  

https://www.marketwatch.com/press-release/adaptive-biotechnologies-announces-medicare-coverage-of-the-clonoseq-assay-for-mrd-testing-in-patients-with-multiple-myeloma-and-acute-lymphoblastic-leukemia-at-multiple-timepoints-throughout-treatment-and-remission-2019-01-17

Jan 17, 2019 – Adaptive Biotechnologies Announces Medicare Coverage of the clonoSEQ® Assay for MRD Testing in Patients with Multiple Myeloma and …

Adaptive receives FDA de novo status for clonoSEQ Assay  

https://www.medicaldevice-network.com/news/adaptive-clonoseq-assay

Oct 1, 2018 – Adaptive Biotechnologies has obtained the FDA de novo designation for clonoSEQ Assay in multiple myeloma and B-cell acute lymphoblastic …

ClonoSEQ Cleared for Residual Cancer Testing | Cancer Discovery  

https://cancerdiscovery.aacrjournals.org/content/early/2018/10/16/2159-8290.CD-NB2018-136

Oct 16, 2018 – The FDA granted the authorization at the end of September for clonoSEQ, from Adaptive Biotechnologies of Seattle, WA, to detect and monitor …

FDA Grants De Novo Designation for Adaptive Biotechnologies …  

https://staging.themmrf.org/2018/09/fda-grants-de-novo-designation-for-adaptive-biotechnologies-clonoseq-assay-to-detect-and-monitor-minimal-residual-disease-mrd-in-patients-with-multiple-myeloma-and-acute-lymphoblastic-leuke

Sep 28, 2018 – The clonoSEQ Assay represents a first-in-class MRD assay that uses next-generation … clonoSEQ is the first and only assay to be cleared by the FDA for MRD …. You can find the login informati…

ClonoSEQ – UCSF Pathology  

http://labmed.ucsf.edu/labmanual/db/data/tests/1566.html

Jun 23, 2017 – Collection Instructions, All samples for clonoSEQ testing should be sent to Adaptive Biotechnologies in Seattle, WA. Due to limited samle …

Adaptive Biotechnologies launches clonoSEQ, a more sensitive …  

https://www.prnewswire.com/news-releases/adaptive-biotechnologies-launches-clonoseq-a-more-sensitive-accurate-assay-to-detect-minimal-residual-disease-mrd-in-blood-based-cancers-182409731.html

Dec 6, 2012 – Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based …